Loading…
Loading…
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 May 2026 – 6PM CET Fagron shareholders approve all proposed resolutions at the General Meetings Fagron, the leading global player in pharmaceutical compounding, today held its Annual and Extraordinary General Meeting of Shareholders. All resolutions proposed by the Board of Directors were approved.
Fagron NV (ARSUF) Q1 2026 Sales/Trading Call Transcript
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2026 – 7 AM CEST Fagron convenes Ordinary and Extraordinary General Meeting on 11 May 2026 Fagron NV invites its shareholders and holders of subscription rights to attend its Ordinary General Meeting and Extraordinary General Meeting, to be held on Monday, 11 May 2026, starting at 15:00 CEST. The Extraordinary General Meeting will be held before notary and will take place immediately following the Ordinary General Meeting.
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the leading global player in pharmaceutical compounding, today publishes its quarterly results for the period ending 31 March 2026. Key Highlights Revenue of €263.4 million, up 10.3% on a reported basis (15.0% at CER 1 ), supported by incremental M&A contribution and outstanding performance in Latin America Organic growth at CER of 3.2%, reflecting positive contributions from all regions Positive momentum in the roll out of our Brands strategy while operational excellence initiatives continue to deliver benefits Completed the Pharmavit acquisition in the Netherlands, with integration of all recently closed transactions progressing as planned FY 2026 guidance: mid- to high-single digit organic sales growth at CER and a REBITDA margin of c.
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 March 2026 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the exercise of subscription rights, 104,200 new shares have been issued on 31 March 2026. In accordance with the Belgian transparency legislation, Fagron notes that its total share capital currently amounts to € 507,462,601.84.
Fagron NV (ARSUF) Q4 2025 Earnings Call Transcript
Fagron NV (OTCPK:ARSUF) Q3 2025 Sales Call October 9, 2025 3:30 AM EDT Company Participants Ignacio Artola Rafael Padilla - CEO & Executive Director Karin de Jong - CFO & Executive Director Conference Call Participants Stijn Demeester - ING Groep N.V., Research Division Frank Claassen - Banque Degroof Petercam S.A.
Fagron, a Belgian pharmaceutical compounding leader, has resolved previous market concerns and provided optimistic 2025-2030 guidance, projecting significant revenue and margin growth. The company expects high single to low double-digit organic revenue growth and improved margins, maintaining leverage ratios within a 2.8-3.5 times EBITDA range. Two scenarios project 2024-2030 revenue growth of 7.5% and 11%, leading to potential REBITDA of 293M EUR and 350M EUR, respectively.
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for ARSUF and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.